KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Vertex Pharmaceuticals (VRTX) Notes Payables (2016 - 2017)

Historic Notes Payables for Vertex Pharmaceuticals (VRTX) over the last 2 years, with Q4 2017 value amounting to $232.4 million.

Vertex Pharmaceuticals' Notes Payables rose 21655.36% to $232.4 million in Q4 2017 from the same period last year, while for Dec 2017 it was $232.4 million, marking a year-over-year increase of 21655.36%. This contributed to the annual value of $232.4 million for FY2017, which is 21655.36% up from last year.
Per Vertex Pharmaceuticals' latest filing, its Notes Payables stood at $232.4 million for Q4 2017, which was up 21655.36% from $190.3 million recorded in Q3 2017.
Over the past 5 years, Vertex Pharmaceuticals' Notes Payables peaked at $232.4 million during Q4 2017, and registered a low of $73.4 million during Q4 2016.